H M Whitehead, J S Gilliland, I V Allen, D R Hadden
{"title":"Growth hormone treatment in adults with growth hormone deficiency: effect on muscle fibre size and proportions.","authors":"H M Whitehead, J S Gilliland, I V Allen, D R Hadden","doi":"10.1111/j.1651-2227.1989.tb11246.x","DOIUrl":null,"url":null,"abstract":"<p><p>The effect of a 6-month period of substitution therapy with recombinant human growth hormone (rhGH) on muscle fibre size and muscle fibre type proportions has been investigated in a group of 13 adults with growth hormone deficiency. All had a peak growth hormone (GH) response to insulin-induced hypoglycaemia of less than 7 mU/l. There was no statistically significant change in the lesser fibre diameter or fibre proportions of either type 1 or type 2 muscle fibres in the rhGH group, as compared with placebo.</p>","PeriodicalId":75408,"journal":{"name":"Acta paediatrica Scandinavica. Supplement","volume":"356 ","pages":"65-7; discussion 68, 73-4"},"PeriodicalIF":0.0000,"publicationDate":"1989-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1651-2227.1989.tb11246.x","citationCount":"34","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta paediatrica Scandinavica. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/j.1651-2227.1989.tb11246.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 34
Abstract
The effect of a 6-month period of substitution therapy with recombinant human growth hormone (rhGH) on muscle fibre size and muscle fibre type proportions has been investigated in a group of 13 adults with growth hormone deficiency. All had a peak growth hormone (GH) response to insulin-induced hypoglycaemia of less than 7 mU/l. There was no statistically significant change in the lesser fibre diameter or fibre proportions of either type 1 or type 2 muscle fibres in the rhGH group, as compared with placebo.